A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
An Open-Label Study to Assess the Efficacy And Safety of Poly(ADP-ribose) Polymerase Inhibitor Fluzoparib（SHR3162）in Patients With Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and BRCA1/2 Mutation
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Listed as NCT03509636, this PHASE1 trial focuses on Ovarian Cancer and remains completed. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 9 times since 2018, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Sep 2022 [monthly]
Completed PHASE1
Status: Unknown Status → Completed · Phase: PHASE2 → PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .